{"nctId":"NCT00791921","briefTitle":"Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)","startDateStruct":{"date":"2008-11"},"conditions":["Rheumatoid Arthritis"],"count":230,"armGroups":[{"label":"CDP870 200mg","type":"EXPERIMENTAL","interventionNames":["Drug: CDP870"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of CDP870"]}],"interventions":[{"name":"CDP870","otherNames":[]},{"name":"Placebo of CDP870","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have a diagnosis of adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 American College of Rheumatology classification criteria.\n* Subjects must have active RA disease as defined by:\n\n  * At least 6 tender joints and 6 swollen joints\n  * ESR of 28 mm/hour or CRP of 2.0 mg/dL\n* Subjects who have failed to respond or have been resistant to at least one DMARD (including MTX)\n* Subjects in whom MTX cannot be administered for any of the reasons(incomplete response/safety concerns)\n\nExclusion Criteria:\n\n* Patients who have a diagnosis of any other inflammatory arthritis\n* Patients who have a secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)\n* Patients who currently have, or who have a history of, a demyelinating or convulsive disease of the central nervous system (eg, multiple sclerosis, epilepsy)\n* Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure\n* Patients who currently have, or who have a history of, tuberculosis\n* Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)\n* Patients who currently have, or who have a history of, malignancy\n* Female patients who are breastfeeding or pregnant, who are of childbearing potential\n* Patients who previously received treatment with 2 or more anti-TNFα drugs or who previously failed to respond to treatment with 1 or more aint-TNFα drugs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 12","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1)Health Assessment Questionnaire-Disability Index (HAQ-DI), 2)C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 24","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1)Health Assessment Questionnaire-Disability Index (HAQ-DI), 2)C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGA-VAS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":116},"commonTop":["Nasopharyngitis","Rheumatoid arthritis","Pharyngitis","Rash","Eczema"]}}}